MeCure Industries Plc Achieves Stable BBB GCR Outlook

MeCure Industries Plc reported a stable BBB GCR outlook for the first half of 2026, affirming its long-term issuer rating of BBB ng and short-term issuer rating of A3 ng. The GCR rating agency noted improvements in the company's competitive position, sound earnings performance, and ongoing product innovation.

MeCure's diversified portfolio includes 140 formulations across five therapeutic classes and an extensive distribution network. The company received halal certification, reinforcing its commitment to quality and compliance, which provides Muslim consumers with confidence in its products.

This certification is expected to enhance trust among customers, healthcare professionals, and distributors. In June 2026, MeCure plans to expand its product portfolio with the introduction of fluconazole capsules and ibuprofen oral suspension, reflecting its focus on affordable local manufacturing of medicines.

As it enters the second half of 2026, MeCure aims to deepen local manufacturing, improve access to quality medicines, and expand its product pipeline to deliver sustainable shareholder value.